Gastrointestinal Cancers (Issue 3) | Special Reports

October 28, 2014

James C. Yao, MD, gives an overview of the questions that still remain regarding the treatment of pancreatic neuroendocrine tumors (NETs).

October 28, 2014

Selection of first-line treatments and the rational sequencing of therapies are the focus of current research in the treatment of pancreatic neuroendocrine tumors (NETs).

October 28, 2014

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the sequencing of agents for pancreatic neuroendocrine tumors (NETs).

October 28, 2014

Using more accurately defined data than previous studies, a team of investigators at the UCSD School of Medicine has characterized the epidemiology of GIST.

October 28, 2014

The number of therapies available for the treatment of metastatic colorectal cancer (mCRC) has increased dramatically since the mid-1990s, when the only option approved by the FDA was 5-fluorouracil (5-FU).

October 27, 2014

Hepatocellular carcinoma remains one of the most common tumors worldwide, and frequently carries a poor prognosis, with most patients being diagnosed at late stages of disease.

October 27, 2014

As with most cancers, early diagnosis and treatment of hepatocellular carcinoma (HCC) may result in more effective treatment and improved outcomes. Unfortunately, most patients with HCC are diagnosed at a late stage, when therapeutic options are limited and prognosis is poor.

October 15, 2014

Tanios Bekaii-Saab, MD, discusses the future of immunotherapy and viral therapy for the treatment of pancreatic cancer.